NIH Plans to Disband RAC

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

Bethesda , Md--NIH director Harold Varmus has announced plants to disband the Recombinant DNA Advisory Committee (RAC). The committee was formed in 1975 as a panel of 24 scientists, ethicists, and others at NIH dedicated to holding those in the field of biogenetics accountable to the public.

Bethesda , Md--NIH director Harold Varmus has announced plantsto disband the Recombinant DNA Advisory Committee (RAC). The committeewas formed in 1975 as a panel of 24 scientists, ethicists, andothers at NIH dedicated to holding those in the field of biogeneticsaccountable to the public.

The RAC created the first safety guidelines for genetically engineeringmicrobes, instituted a formal review system for studies involvinginsertion of new genes into humans, and, in 1990, gave the firstapproval of a human gene therapy experiment. RAC approval wasrequired before the FDA would consider any gene therapy proposal.

Now, Dr. Varmus believes the RAC is no longer necessary, as theFDA can handle all new proposals with the help of ad hoc committeesconvened as needed.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content